Global Cell Therapy for Solid Tumor Supply, Demand and Key Producers, 2026-2032
The global Cell Therapy for Solid Tumor market size is expected to reach $ 7768 million by 2032, rising at a market growth of 19.7% CAGR during the forecast period (2026-2032).
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
This report studies the global Cell Therapy for Solid Tumor demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cell Therapy for Solid Tumor, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cell Therapy for Solid Tumor that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cell Therapy for Solid Tumor total market, 2021-2032, (USD Million)
Global Cell Therapy for Solid Tumor total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cell Therapy for Solid Tumor total market, key domestic companies, and share, (USD Million)
Global Cell Therapy for Solid Tumor revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cell Therapy for Solid Tumor total market by Type, CAGR, 2021-2032, (USD Million)
Global Cell Therapy for Solid Tumor total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cell Therapy for Solid Tumor market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Iovance Biotherapeutics, Adaptimmune, Immatics, CARSgen Therapeutics, JW Therapeutics, Legend Biotech, Gracell Biotechnologies, Fosun Kite, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cell Therapy for Solid Tumor market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cell Therapy for Solid Tumor Market, By Region:
1. How big is the global Cell Therapy for Solid Tumor market?
2. What is the demand of the global Cell Therapy for Solid Tumor market?
3. What is the year over year growth of the global Cell Therapy for Solid Tumor market?
4. What is the total value of the global Cell Therapy for Solid Tumor market?
5. Who are the Major Players in the global Cell Therapy for Solid Tumor market?
6. What are the growth factors driving the market demand?
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
This report studies the global Cell Therapy for Solid Tumor demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cell Therapy for Solid Tumor, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cell Therapy for Solid Tumor that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cell Therapy for Solid Tumor total market, 2021-2032, (USD Million)
Global Cell Therapy for Solid Tumor total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cell Therapy for Solid Tumor total market, key domestic companies, and share, (USD Million)
Global Cell Therapy for Solid Tumor revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cell Therapy for Solid Tumor total market by Type, CAGR, 2021-2032, (USD Million)
Global Cell Therapy for Solid Tumor total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cell Therapy for Solid Tumor market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Iovance Biotherapeutics, Adaptimmune, Immatics, CARSgen Therapeutics, JW Therapeutics, Legend Biotech, Gracell Biotechnologies, Fosun Kite, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cell Therapy for Solid Tumor market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cell Therapy for Solid Tumor Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- CAR-T Therapy
- TCR-T Therapy
- TIL Therapy
- CAR-NK Therapy
- Tumor-Infiltrating NK Or T Cells
- Other
- Autologous Therapy
- Allogeneic Therapy
- Gene-Edited Therapy
- Armored Cell Therapy
- Combination Therapy
- Other
- Melanoma Products
- Gastrointestinal Tumor Products
- Liver Cancer Products
- Lung Cancer Products
- Gynecologic Tumor Products
- Other
- Melanoma
- Lung Cancer
- Liver Cancer
- Gastric And Colorectal Cancer
- Ovarian Cancer
- Other
- Iovance Biotherapeutics
- Adaptimmune
- Immatics
- CARSgen Therapeutics
- JW Therapeutics
- Legend Biotech
- Gracell Biotechnologies
- Fosun Kite
1. How big is the global Cell Therapy for Solid Tumor market?
2. What is the demand of the global Cell Therapy for Solid Tumor market?
3. What is the year over year growth of the global Cell Therapy for Solid Tumor market?
4. What is the total value of the global Cell Therapy for Solid Tumor market?
5. Who are the Major Players in the global Cell Therapy for Solid Tumor market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Cell Therapy for Solid Tumor Introduction
1.2 World Cell Therapy for Solid Tumor Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cell Therapy for Solid Tumor Total Market by Region (by Headquarter Location)
1.3.1 World Cell Therapy for Solid Tumor Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.3 China Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.4 Europe Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.5 Japan Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.6 South Korea Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.7 ASEAN Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.8 India Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cell Therapy for Solid Tumor Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.2 World Cell Therapy for Solid Tumor Consumption Value by Region
2.2.1 World Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026)
2.2.2 World Cell Therapy for Solid Tumor Consumption Value Forecast by Region (2027-2032)
2.3 United States Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.4 China Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.5 Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.6 Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.7 South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.8 ASEAN Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.9 India Cell Therapy for Solid Tumor Consumption Value (2021-2032)
3 WORLD CELL THERAPY FOR SOLID TUMOR COMPANIES COMPETITIVE ANALYSIS
3.1 World Cell Therapy for Solid Tumor Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cell Therapy for Solid Tumor Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cell Therapy for Solid Tumor in 2025
3.2.3 Global Concentration Ratios (CR8) for Cell Therapy for Solid Tumor in 2025
3.3 Cell Therapy for Solid Tumor Company Evaluation Quadrant
3.4 Cell Therapy for Solid Tumor Market: Overall Company Footprint Analysis
3.4.1 Cell Therapy for Solid Tumor Market: Region Footprint
3.4.2 Cell Therapy for Solid Tumor Market: Company Product Type Footprint
3.4.3 Cell Therapy for Solid Tumor Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cell Therapy for Solid Tumor Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cell Therapy for Solid Tumor Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cell Therapy for Solid Tumor Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cell Therapy for Solid Tumor Consumption Value Comparison
4.2.1 United States VS China: Cell Therapy for Solid Tumor Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cell Therapy for Solid Tumor Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cell Therapy for Solid Tumor Companies and Market Share, 2021-2026
4.3.1 United States Based Cell Therapy for Solid Tumor Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026)
4.4 China Based Companies Cell Therapy for Solid Tumor Revenue and Market Share, 2021-2026
4.4.1 China Based Cell Therapy for Solid Tumor Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026)
4.5 Rest of World Based Cell Therapy for Solid Tumor Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cell Therapy for Solid Tumor Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cell Therapy for Solid Tumor Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 CAR-T Therapy
5.2.2 TCR-T Therapy
5.2.3 TIL Therapy
5.2.4 CAR-NK Therapy
5.2.5 Tumor-Infiltrating NK Or T Cells
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
5.3.2 World Cell Therapy for Solid Tumor Market Size by Type (2027-2032)
5.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY CELL SOURCE
6.1 World Cell Therapy for Solid Tumor Market Size Overview by Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Cell Source
6.2.1 Autologous Therapy
6.2.2 Allogeneic Therapy
6.2.3 Gene-Edited Therapy
6.2.4 Armored Cell Therapy
6.2.5 Combination Therapy
6.2.6 Other
6.3 Market Segment by Cell Source
6.3.1 World Cell Therapy for Solid Tumor Market Size by Cell Source (2021-2026)
6.3.2 World Cell Therapy for Solid Tumor Market Size by Cell Source (2027-2032)
6.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2027-2032)
7 MARKET ANALYSIS BY INDICATION
7.1 World Cell Therapy for Solid Tumor Market Size Overview by Indication: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Indication
7.2.1 Melanoma Products
7.2.2 Gastrointestinal Tumor Products
7.2.3 Liver Cancer Products
7.2.4 Lung Cancer Products
7.2.5 Gynecologic Tumor Products
7.2.6 Other
7.3 Market Segment by Indication
7.3.1 World Cell Therapy for Solid Tumor Market Size by Indication (2021-2026)
7.3.2 World Cell Therapy for Solid Tumor Market Size by Indication (2027-2032)
7.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Indication (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cell Therapy for Solid Tumor Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Melanoma
8.2.2 Lung Cancer
8.2.3 Liver Cancer
8.2.4 Gastric And Colorectal Cancer
8.2.5 Ovarian Cancer
8.2.6 Other
8.3 Market Segment by Application
8.3.1 World Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
8.3.2 World Cell Therapy for Solid Tumor Market Size by Application (2027-2032)
8.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Iovance Biotherapeutics
9.1.1 Iovance Biotherapeutics Details
9.1.2 Iovance Biotherapeutics Major Business
9.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Services
9.1.4 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Iovance Biotherapeutics Recent Developments/Updates
9.1.6 Iovance Biotherapeutics Competitive Strengths & Weaknesses
9.2 Adaptimmune
9.2.1 Adaptimmune Details
9.2.2 Adaptimmune Major Business
9.2.3 Adaptimmune Cell Therapy for Solid Tumor Product and Services
9.2.4 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Adaptimmune Recent Developments/Updates
9.2.6 Adaptimmune Competitive Strengths & Weaknesses
9.3 Immatics
9.3.1 Immatics Details
9.3.2 Immatics Major Business
9.3.3 Immatics Cell Therapy for Solid Tumor Product and Services
9.3.4 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Immatics Recent Developments/Updates
9.3.6 Immatics Competitive Strengths & Weaknesses
9.4 CARSgen Therapeutics
9.4.1 CARSgen Therapeutics Details
9.4.2 CARSgen Therapeutics Major Business
9.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Services
9.4.4 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CARSgen Therapeutics Recent Developments/Updates
9.4.6 CARSgen Therapeutics Competitive Strengths & Weaknesses
9.5 JW Therapeutics
9.5.1 JW Therapeutics Details
9.5.2 JW Therapeutics Major Business
9.5.3 JW Therapeutics Cell Therapy for Solid Tumor Product and Services
9.5.4 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 JW Therapeutics Recent Developments/Updates
9.5.6 JW Therapeutics Competitive Strengths & Weaknesses
9.6 Legend Biotech
9.6.1 Legend Biotech Details
9.6.2 Legend Biotech Major Business
9.6.3 Legend Biotech Cell Therapy for Solid Tumor Product and Services
9.6.4 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Legend Biotech Recent Developments/Updates
9.6.6 Legend Biotech Competitive Strengths & Weaknesses
9.7 Gracell Biotechnologies
9.7.1 Gracell Biotechnologies Details
9.7.2 Gracell Biotechnologies Major Business
9.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Services
9.7.4 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Gracell Biotechnologies Recent Developments/Updates
9.7.6 Gracell Biotechnologies Competitive Strengths & Weaknesses
9.8 Fosun Kite
9.8.1 Fosun Kite Details
9.8.2 Fosun Kite Major Business
9.8.3 Fosun Kite Cell Therapy for Solid Tumor Product and Services
9.8.4 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Fosun Kite Recent Developments/Updates
9.8.6 Fosun Kite Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cell Therapy for Solid Tumor Industry Chain
10.2 Cell Therapy for Solid Tumor Upstream Analysis
10.3 Cell Therapy for Solid Tumor Midstream Analysis
10.4 Cell Therapy for Solid Tumor Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Cell Therapy for Solid Tumor Introduction
1.2 World Cell Therapy for Solid Tumor Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cell Therapy for Solid Tumor Total Market by Region (by Headquarter Location)
1.3.1 World Cell Therapy for Solid Tumor Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.3 China Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.4 Europe Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.5 Japan Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.6 South Korea Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.7 ASEAN Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.3.8 India Based Company Cell Therapy for Solid Tumor Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cell Therapy for Solid Tumor Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.2 World Cell Therapy for Solid Tumor Consumption Value by Region
2.2.1 World Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026)
2.2.2 World Cell Therapy for Solid Tumor Consumption Value Forecast by Region (2027-2032)
2.3 United States Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.4 China Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.5 Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.6 Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.7 South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.8 ASEAN Cell Therapy for Solid Tumor Consumption Value (2021-2032)
2.9 India Cell Therapy for Solid Tumor Consumption Value (2021-2032)
3 WORLD CELL THERAPY FOR SOLID TUMOR COMPANIES COMPETITIVE ANALYSIS
3.1 World Cell Therapy for Solid Tumor Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cell Therapy for Solid Tumor Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cell Therapy for Solid Tumor in 2025
3.2.3 Global Concentration Ratios (CR8) for Cell Therapy for Solid Tumor in 2025
3.3 Cell Therapy for Solid Tumor Company Evaluation Quadrant
3.4 Cell Therapy for Solid Tumor Market: Overall Company Footprint Analysis
3.4.1 Cell Therapy for Solid Tumor Market: Region Footprint
3.4.2 Cell Therapy for Solid Tumor Market: Company Product Type Footprint
3.4.3 Cell Therapy for Solid Tumor Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cell Therapy for Solid Tumor Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cell Therapy for Solid Tumor Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cell Therapy for Solid Tumor Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cell Therapy for Solid Tumor Consumption Value Comparison
4.2.1 United States VS China: Cell Therapy for Solid Tumor Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cell Therapy for Solid Tumor Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cell Therapy for Solid Tumor Companies and Market Share, 2021-2026
4.3.1 United States Based Cell Therapy for Solid Tumor Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026)
4.4 China Based Companies Cell Therapy for Solid Tumor Revenue and Market Share, 2021-2026
4.4.1 China Based Cell Therapy for Solid Tumor Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026)
4.5 Rest of World Based Cell Therapy for Solid Tumor Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cell Therapy for Solid Tumor Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cell Therapy for Solid Tumor Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 CAR-T Therapy
5.2.2 TCR-T Therapy
5.2.3 TIL Therapy
5.2.4 CAR-NK Therapy
5.2.5 Tumor-Infiltrating NK Or T Cells
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
5.3.2 World Cell Therapy for Solid Tumor Market Size by Type (2027-2032)
5.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY CELL SOURCE
6.1 World Cell Therapy for Solid Tumor Market Size Overview by Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Cell Source
6.2.1 Autologous Therapy
6.2.2 Allogeneic Therapy
6.2.3 Gene-Edited Therapy
6.2.4 Armored Cell Therapy
6.2.5 Combination Therapy
6.2.6 Other
6.3 Market Segment by Cell Source
6.3.1 World Cell Therapy for Solid Tumor Market Size by Cell Source (2021-2026)
6.3.2 World Cell Therapy for Solid Tumor Market Size by Cell Source (2027-2032)
6.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2027-2032)
7 MARKET ANALYSIS BY INDICATION
7.1 World Cell Therapy for Solid Tumor Market Size Overview by Indication: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Indication
7.2.1 Melanoma Products
7.2.2 Gastrointestinal Tumor Products
7.2.3 Liver Cancer Products
7.2.4 Lung Cancer Products
7.2.5 Gynecologic Tumor Products
7.2.6 Other
7.3 Market Segment by Indication
7.3.1 World Cell Therapy for Solid Tumor Market Size by Indication (2021-2026)
7.3.2 World Cell Therapy for Solid Tumor Market Size by Indication (2027-2032)
7.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Indication (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cell Therapy for Solid Tumor Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Melanoma
8.2.2 Lung Cancer
8.2.3 Liver Cancer
8.2.4 Gastric And Colorectal Cancer
8.2.5 Ovarian Cancer
8.2.6 Other
8.3 Market Segment by Application
8.3.1 World Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
8.3.2 World Cell Therapy for Solid Tumor Market Size by Application (2027-2032)
8.3.3 World Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Iovance Biotherapeutics
9.1.1 Iovance Biotherapeutics Details
9.1.2 Iovance Biotherapeutics Major Business
9.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Services
9.1.4 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Iovance Biotherapeutics Recent Developments/Updates
9.1.6 Iovance Biotherapeutics Competitive Strengths & Weaknesses
9.2 Adaptimmune
9.2.1 Adaptimmune Details
9.2.2 Adaptimmune Major Business
9.2.3 Adaptimmune Cell Therapy for Solid Tumor Product and Services
9.2.4 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Adaptimmune Recent Developments/Updates
9.2.6 Adaptimmune Competitive Strengths & Weaknesses
9.3 Immatics
9.3.1 Immatics Details
9.3.2 Immatics Major Business
9.3.3 Immatics Cell Therapy for Solid Tumor Product and Services
9.3.4 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Immatics Recent Developments/Updates
9.3.6 Immatics Competitive Strengths & Weaknesses
9.4 CARSgen Therapeutics
9.4.1 CARSgen Therapeutics Details
9.4.2 CARSgen Therapeutics Major Business
9.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Services
9.4.4 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CARSgen Therapeutics Recent Developments/Updates
9.4.6 CARSgen Therapeutics Competitive Strengths & Weaknesses
9.5 JW Therapeutics
9.5.1 JW Therapeutics Details
9.5.2 JW Therapeutics Major Business
9.5.3 JW Therapeutics Cell Therapy for Solid Tumor Product and Services
9.5.4 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 JW Therapeutics Recent Developments/Updates
9.5.6 JW Therapeutics Competitive Strengths & Weaknesses
9.6 Legend Biotech
9.6.1 Legend Biotech Details
9.6.2 Legend Biotech Major Business
9.6.3 Legend Biotech Cell Therapy for Solid Tumor Product and Services
9.6.4 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Legend Biotech Recent Developments/Updates
9.6.6 Legend Biotech Competitive Strengths & Weaknesses
9.7 Gracell Biotechnologies
9.7.1 Gracell Biotechnologies Details
9.7.2 Gracell Biotechnologies Major Business
9.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Services
9.7.4 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Gracell Biotechnologies Recent Developments/Updates
9.7.6 Gracell Biotechnologies Competitive Strengths & Weaknesses
9.8 Fosun Kite
9.8.1 Fosun Kite Details
9.8.2 Fosun Kite Major Business
9.8.3 Fosun Kite Cell Therapy for Solid Tumor Product and Services
9.8.4 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Fosun Kite Recent Developments/Updates
9.8.6 Fosun Kite Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cell Therapy for Solid Tumor Industry Chain
10.2 Cell Therapy for Solid Tumor Upstream Analysis
10.3 Cell Therapy for Solid Tumor Midstream Analysis
10.4 Cell Therapy for Solid Tumor Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Cell Therapy for Solid Tumor Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cell Therapy for Solid Tumor Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cell Therapy for Solid Tumor Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cell Therapy for Solid Tumor Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cell Therapy for Solid Tumor Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cell Therapy for Solid Tumor Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cell Therapy for Solid Tumor Players in 2025
Table 12. World Cell Therapy for Solid Tumor Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cell Therapy for Solid Tumor Company Evaluation Quadrant
Table 14. Head Office of Key Cell Therapy for Solid Tumor Players
Table 15. Cell Therapy for Solid Tumor Market: Company Product Type Footprint
Table 16. Cell Therapy for Solid Tumor Market: Company Product Application Footprint
Table 17. Cell Therapy for Solid Tumor Mergers & Acquisitions Activity
Table 18. United States VS China Cell Therapy for Solid Tumor Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cell Therapy for Solid Tumor Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cell Therapy for Solid Tumor Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 23. China Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cell Therapy for Solid Tumor Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 29. World Cell Therapy for Solid Tumor Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cell Therapy for Solid Tumor Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cell Therapy for Solid Tumor Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cell Therapy for Solid Tumor Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Cell Therapy for Solid Tumor Market Size Value by Cell Source (2021-2026) & (USD Million)
Table 34. World Cell Therapy for Solid Tumor Market Size by Cell Source (2027-2032) & (USD Million)
Table 35. World Cell Therapy for Solid Tumor Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Table 36. World Cell Therapy for Solid Tumor Market Size Value by Indication (2021-2026) & (USD Million)
Table 37. World Cell Therapy for Solid Tumor Market Size by Indication (2027-2032) & (USD Million)
Table 38. World Cell Therapy for Solid Tumor Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cell Therapy for Solid Tumor Market Size by Application (2027-2032) & (USD Million)
Table 41. Iovance Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Iovance Biotherapeutics Major Business
Table 43. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Services
Table 44. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Iovance Biotherapeutics Recent Developments/Updates
Table 46. Iovance Biotherapeutics Competitive Strengths & Weaknesses
Table 47. Adaptimmune Basic Information, Manufacturing Base and Competitors
Table 48. Adaptimmune Major Business
Table 49. Adaptimmune Cell Therapy for Solid Tumor Product and Services
Table 50. Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Adaptimmune Recent Developments/Updates
Table 52. Adaptimmune Competitive Strengths & Weaknesses
Table 53. Immatics Basic Information, Manufacturing Base and Competitors
Table 54. Immatics Major Business
Table 55. Immatics Cell Therapy for Solid Tumor Product and Services
Table 56. Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Immatics Recent Developments/Updates
Table 58. Immatics Competitive Strengths & Weaknesses
Table 59. CARSgen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. CARSgen Therapeutics Major Business
Table 61. CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Services
Table 62. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CARSgen Therapeutics Recent Developments/Updates
Table 64. CARSgen Therapeutics Competitive Strengths & Weaknesses
Table 65. JW Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. JW Therapeutics Major Business
Table 67. JW Therapeutics Cell Therapy for Solid Tumor Product and Services
Table 68. JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. JW Therapeutics Recent Developments/Updates
Table 70. JW Therapeutics Competitive Strengths & Weaknesses
Table 71. Legend Biotech Basic Information, Manufacturing Base and Competitors
Table 72. Legend Biotech Major Business
Table 73. Legend Biotech Cell Therapy for Solid Tumor Product and Services
Table 74. Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Legend Biotech Recent Developments/Updates
Table 76. Legend Biotech Competitive Strengths & Weaknesses
Table 77. Gracell Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 78. Gracell Biotechnologies Major Business
Table 79. Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Services
Table 80. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Gracell Biotechnologies Recent Developments/Updates
Table 82. Gracell Biotechnologies Competitive Strengths & Weaknesses
Table 83. Fosun Kite Basic Information, Manufacturing Base and Competitors
Table 84. Fosun Kite Major Business
Table 85. Fosun Kite Cell Therapy for Solid Tumor Product and Services
Table 86. Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Fosun Kite Recent Developments/Updates
Table 88. Fosun Kite Competitive Strengths & Weaknesses
Table 89. Global Key Players of Cell Therapy for Solid Tumor Upstream (Raw Materials)
Table 90. Global Cell Therapy for Solid Tumor Typical Customers
Table 1. World Cell Therapy for Solid Tumor Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cell Therapy for Solid Tumor Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cell Therapy for Solid Tumor Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cell Therapy for Solid Tumor Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cell Therapy for Solid Tumor Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cell Therapy for Solid Tumor Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cell Therapy for Solid Tumor Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cell Therapy for Solid Tumor Players in 2025
Table 12. World Cell Therapy for Solid Tumor Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cell Therapy for Solid Tumor Company Evaluation Quadrant
Table 14. Head Office of Key Cell Therapy for Solid Tumor Players
Table 15. Cell Therapy for Solid Tumor Market: Company Product Type Footprint
Table 16. Cell Therapy for Solid Tumor Market: Company Product Application Footprint
Table 17. Cell Therapy for Solid Tumor Mergers & Acquisitions Activity
Table 18. United States VS China Cell Therapy for Solid Tumor Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cell Therapy for Solid Tumor Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cell Therapy for Solid Tumor Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 23. China Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cell Therapy for Solid Tumor Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cell Therapy for Solid Tumor Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cell Therapy for Solid Tumor Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cell Therapy for Solid Tumor Revenue Market Share (2021-2026)
Table 29. World Cell Therapy for Solid Tumor Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cell Therapy for Solid Tumor Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cell Therapy for Solid Tumor Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cell Therapy for Solid Tumor Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Cell Therapy for Solid Tumor Market Size Value by Cell Source (2021-2026) & (USD Million)
Table 34. World Cell Therapy for Solid Tumor Market Size by Cell Source (2027-2032) & (USD Million)
Table 35. World Cell Therapy for Solid Tumor Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Table 36. World Cell Therapy for Solid Tumor Market Size Value by Indication (2021-2026) & (USD Million)
Table 37. World Cell Therapy for Solid Tumor Market Size by Indication (2027-2032) & (USD Million)
Table 38. World Cell Therapy for Solid Tumor Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cell Therapy for Solid Tumor Market Size by Application (2027-2032) & (USD Million)
Table 41. Iovance Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Iovance Biotherapeutics Major Business
Table 43. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product and Services
Table 44. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Iovance Biotherapeutics Recent Developments/Updates
Table 46. Iovance Biotherapeutics Competitive Strengths & Weaknesses
Table 47. Adaptimmune Basic Information, Manufacturing Base and Competitors
Table 48. Adaptimmune Major Business
Table 49. Adaptimmune Cell Therapy for Solid Tumor Product and Services
Table 50. Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Adaptimmune Recent Developments/Updates
Table 52. Adaptimmune Competitive Strengths & Weaknesses
Table 53. Immatics Basic Information, Manufacturing Base and Competitors
Table 54. Immatics Major Business
Table 55. Immatics Cell Therapy for Solid Tumor Product and Services
Table 56. Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Immatics Recent Developments/Updates
Table 58. Immatics Competitive Strengths & Weaknesses
Table 59. CARSgen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. CARSgen Therapeutics Major Business
Table 61. CARSgen Therapeutics Cell Therapy for Solid Tumor Product and Services
Table 62. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CARSgen Therapeutics Recent Developments/Updates
Table 64. CARSgen Therapeutics Competitive Strengths & Weaknesses
Table 65. JW Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. JW Therapeutics Major Business
Table 67. JW Therapeutics Cell Therapy for Solid Tumor Product and Services
Table 68. JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. JW Therapeutics Recent Developments/Updates
Table 70. JW Therapeutics Competitive Strengths & Weaknesses
Table 71. Legend Biotech Basic Information, Manufacturing Base and Competitors
Table 72. Legend Biotech Major Business
Table 73. Legend Biotech Cell Therapy for Solid Tumor Product and Services
Table 74. Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Legend Biotech Recent Developments/Updates
Table 76. Legend Biotech Competitive Strengths & Weaknesses
Table 77. Gracell Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 78. Gracell Biotechnologies Major Business
Table 79. Gracell Biotechnologies Cell Therapy for Solid Tumor Product and Services
Table 80. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Gracell Biotechnologies Recent Developments/Updates
Table 82. Gracell Biotechnologies Competitive Strengths & Weaknesses
Table 83. Fosun Kite Basic Information, Manufacturing Base and Competitors
Table 84. Fosun Kite Major Business
Table 85. Fosun Kite Cell Therapy for Solid Tumor Product and Services
Table 86. Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Fosun Kite Recent Developments/Updates
Table 88. Fosun Kite Competitive Strengths & Weaknesses
Table 89. Global Key Players of Cell Therapy for Solid Tumor Upstream (Raw Materials)
Table 90. Global Cell Therapy for Solid Tumor Typical Customers
LIST OF FIGURES
Figure 1. Cell Therapy for Solid Tumor Picture
Figure 2. World Cell Therapy for Solid Tumor Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cell Therapy for Solid Tumor Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cell Therapy for Solid Tumor Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 13. Cell Therapy for Solid Tumor Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cell Therapy for Solid Tumor by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cell Therapy for Solid Tumor Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cell Therapy for Solid Tumor Markets in 2025
Figure 27. United States VS China: Cell Therapy for Solid Tumor Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cell Therapy for Solid Tumor Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cell Therapy for Solid Tumor Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cell Therapy for Solid Tumor Market Size Market Share by Type in 2025
Figure 31. CAR-T Therapy
Figure 32. TCR-T Therapy
Figure 33. TIL Therapy
Figure 34. CAR-NK Therapy
Figure 35. Tumor-Infiltrating NK Or T Cells
Figure 36. Other
Figure 37. World Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2032)
Figure 38. World Cell Therapy for Solid Tumor Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 39. World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source in 2025
Figure 40. Autologous Therapy
Figure 41. Allogeneic Therapy
Figure 42. Gene-Edited Therapy
Figure 43. Armored Cell Therapy
Figure 44. Combination Therapy
Figure 45. Other
Figure 46. World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2032)
Figure 47. World Cell Therapy for Solid Tumor Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Figure 48. World Cell Therapy for Solid Tumor Market Size Market Share by Indication in 2025
Figure 49. Melanoma Products
Figure 50. Gastrointestinal Tumor Products
Figure 51. Liver Cancer Products
Figure 52. Lung Cancer Products
Figure 53. Gynecologic Tumor Products
Figure 54. Other
Figure 55. World Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2032)
Figure 56. World Cell Therapy for Solid Tumor Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 57. World Cell Therapy for Solid Tumor Market Size Market Share by Application in 2025
Figure 58. Melanoma
Figure 59. Lung Cancer
Figure 60. Liver Cancer
Figure 61. Gastric And Colorectal Cancer
Figure 62. Ovarian Cancer
Figure 63. Other
Figure 64. World Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2032)
Figure 65. Cell Therapy for Solid Tumor Industrial Chain
Figure 66. Methodology
Figure 67. Research Process and Data Source
Figure 1. Cell Therapy for Solid Tumor Picture
Figure 2. World Cell Therapy for Solid Tumor Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cell Therapy for Solid Tumor Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cell Therapy for Solid Tumor Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cell Therapy for Solid Tumor Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cell Therapy for Solid Tumor Revenue (2021-2032) & (USD Million)
Figure 13. Cell Therapy for Solid Tumor Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cell Therapy for Solid Tumor Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cell Therapy for Solid Tumor Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cell Therapy for Solid Tumor by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cell Therapy for Solid Tumor Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cell Therapy for Solid Tumor Markets in 2025
Figure 27. United States VS China: Cell Therapy for Solid Tumor Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cell Therapy for Solid Tumor Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cell Therapy for Solid Tumor Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cell Therapy for Solid Tumor Market Size Market Share by Type in 2025
Figure 31. CAR-T Therapy
Figure 32. TCR-T Therapy
Figure 33. TIL Therapy
Figure 34. CAR-NK Therapy
Figure 35. Tumor-Infiltrating NK Or T Cells
Figure 36. Other
Figure 37. World Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2032)
Figure 38. World Cell Therapy for Solid Tumor Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 39. World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source in 2025
Figure 40. Autologous Therapy
Figure 41. Allogeneic Therapy
Figure 42. Gene-Edited Therapy
Figure 43. Armored Cell Therapy
Figure 44. Combination Therapy
Figure 45. Other
Figure 46. World Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2032)
Figure 47. World Cell Therapy for Solid Tumor Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Figure 48. World Cell Therapy for Solid Tumor Market Size Market Share by Indication in 2025
Figure 49. Melanoma Products
Figure 50. Gastrointestinal Tumor Products
Figure 51. Liver Cancer Products
Figure 52. Lung Cancer Products
Figure 53. Gynecologic Tumor Products
Figure 54. Other
Figure 55. World Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2032)
Figure 56. World Cell Therapy for Solid Tumor Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 57. World Cell Therapy for Solid Tumor Market Size Market Share by Application in 2025
Figure 58. Melanoma
Figure 59. Lung Cancer
Figure 60. Liver Cancer
Figure 61. Gastric And Colorectal Cancer
Figure 62. Ovarian Cancer
Figure 63. Other
Figure 64. World Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2032)
Figure 65. Cell Therapy for Solid Tumor Industrial Chain
Figure 66. Methodology
Figure 67. Research Process and Data Source
